Abstract
Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens. Here, we developed an integrated approach combining synthetic, computational and structural methods with in vitro antibody selection and in vivo immunization to design, produce and validate nature-inspired nanoparticle-based reagents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach resulted in two innovations: (i) a thermostable nasal vaccine called ADDoCoV, displaying multiple copies of a SARS-CoV-2 receptor binding motif derived epitope and (ii) a multivalent nanoparticle superbinder, called Gigabody, against SARS-CoV-2 including immune-evasive variants of concern (VOCs). In vitro generated neutralizing nanobodies and electron cryo-microscopy established authenticity and accessibility of epitopes displayed by ADDoCoV. Gigabody comprising multimerized nanobodies prevented SARS-CoV-2 virion attachment with picomolar EC50. Vaccinating mice resulted in antibodies cross-reacting with VOCs including Delta and Omicron. Our study elucidates Adenovirus-derived dodecamer (ADDomer)-based nanoparticles for use in active and passive immunization and provides a blueprint for crafting reagents to combat respiratory viral infections.
All Related Versions
Funding Information
  • Horizon 2020 (899670)
  • European Research Council (834631)
  • EPSRC Future Vaccine Manufacturing and Research Hub (EP/R013764/1)
  • EPSRC (EP/M022609/1)
  • British Society for Antimicrobial Chemotherapy
  • MRC (MR/V027506/1, MR/R020566/1, MR/V027506/1)
  • United States Food and Drug Administration (HHSF223201510104C)
  • Federal Ministry of Education and Research of Germany and the Max Planck Society
  • European Research Council (294852)
  • Elisabeth Muerer Foundation
  • University of Bristol (BB/L01386X/1)
  • BBSRC (BB/R000484/1)
  • Wellcome Trust (221708/Z/20/Z, 206181/Z/17/Z, 202904/Z/16/Z)

This publication has 81 references indexed in Scilit: